Search

Your search keyword '"Nguyen, P.L."' showing total 331 results
Start Over Author "Nguyen, P.L."
331 results on '"Nguyen, P.L."'

1. Cross-Comparison Individual Patient Level Analysis of Three Gene Expression Signatures in Localized Prostate in over 50,000 Men

Author

Jia, A.Y., primary, Sun, Y., additional, Baydoun, A., additional, Zaorsky, N.G., additional, Vince, R.A., additional, Shoag, J.E., additional, Brown, J., additional, Barata, P., additional, Dess, R.T., additional, Jackson, W.C., additional, Roy, S., additional, Nguyen, P.L., additional, Berlin, A., additional, Mehra, R., additional, Schaeffer, E.M., additional, Kashani, R., additional, Kishan, A.U., additional, Morgan, T.M., additional, and Spratt, D.E., additional

Published
2023
Full Text
View/download PDF

5. FORMULA-509: A Multicenter Randomized Trial of Post-Operative Salvage Radiotherapy (SRT) and 6 Months of GnRH Agonist with Either Bicalutamide or Abiraterone Acetate/Prednisone (AAP) and Apalutamide (Apa) Post-Radical Prostatectomy (RP)

Author

Nguyen, P.L., primary, Kollmeier, M.A., additional, Rathkopf, D., additional, Hoffman, K.E., additional, Zurita-Saavedra, A., additional, Spratt, D.E., additional, Dess, R.T., additional, Liauw, S., additional, Szmulewitz, R., additional, Einstein, D.J., additional, Bubley, G., additional, Yu, J.B., additional, An, Y., additional, Wong, A.C., additional, Feng, F.Y., additional, Mckay, R.R., additional, Rose, B.S., additional, Shin, K.Y., additional, Kibel, A., additional, and Taplin, M.E.A., additional

Published
2023
Full Text
View/download PDF

6. Health Equity Achievement in Radiation Therapy (HEART) Score: A Social Prognosis

Author

Patel, A.M., primary, Dee, E.C., additional, Hubbard, A., additional, Milligan, M.G., additional, Ebner, D.K., additional, Alcorn, S.R., additional, LaVigne, A., additional, Kudner, R.F., additional, Mayo, C., additional, Adler, D., additional, Suggs, K., additional, Greathouse, A., additional, Ludwig, M.S., additional, Nguyen, P.L., additional, Waddle, M.R., additional, Thompson, R.F., additional, Mahal, B.A., additional, and Yamoah, K., additional

Published
2023
Full Text
View/download PDF

7. Long-Term Follow-Up Analysis of NRG Oncology RTOG 0415: A Randomized Phase III Non-Inferiority Study Comparing Two Fractionation Schedules in Patients with Favorable-Risk Prostate Cancer

Author

Lee, W.R., primary, Dignam, J.J., additional, Amin, M., additional, Bruner, D.W., additional, Low, D., additional, Swanson, G.P., additional, Shah, A.B., additional, D'Souza, D.P., additional, Michalski, J.M., additional, Dayes, I., additional, Seaward, S.A., additional, Hall, W.A., additional, Nguyen, P.L., additional, Pisansky, T.M., additional, Faria, S.L., additional, Chen, Y., additional, Rodgers, J., additional, and Sandler, H.M., additional

Published
2023
Full Text
View/download PDF

9. Association between Artificial Intelligence-Derived Tumor Volume and Oncologic Outcomes for Localized Prostate Cancer Treated with Radiation Therapy

Author

Yang, D.D., primary, Lee, L.K., additional, Tsui, J.M.G., additional, Leeman, J.E., additional, Lee, K.N., additional, McClure, H.M., additional, Sudhyadhom, A., additional, Guthier, C.V., additional, Mouw, K.W., additional, Martin, N.E., additional, Orio, P.F., additional, Nguyen, P.L., additional, DAmico, A.V., additional, and King, M.T., additional

Published
2023
Full Text
View/download PDF

13. Management of Patients with Advanced Prostate Cancer. Part I: Intermediate-/High-risk and Locally Advanced Disease, Biochemical Relapse, and Side Effects of Hormonal Treatment: Report of the Advanced Prostate Cancer Consensus Conference 2022

Author

Gillessen, S., Bossi, A., Davis, I.D., Bono, J. de, Fizazi, K., James, N.D., Mottet, N., Shore, N., Small, E., Smith, M., Sweeney, C., Tombal, B., Antonarakis, E.S., Aparicio, A.M., Armstrong, A.J., Attard, G., Beer, T.M., Beltran, H., Bjartell, A., Blanchard, P., Briganti, A., Bristow, R.G., Bulbul, M., Caffo, O., Castellano, D., Castro, E., Cheng, H.H., Chi, K.N., Chowdhury, S., Clarke, C.S., Clarke, N., Daugaard, G., Santis, M. de, Duran, I., Eeles, R., Efstathiou, E., Efstathiou, J., Ekeke, O. Ngozi, Evans, C.P., Fanti, S., Feng, F.Y., Fonteyne, V., Fossati, N., Frydenberg, M., George, D., Gleave, M., Gravis, G., Halabi, S., Heinrich, D., Herrmann, K., Higano, C., Hofman, M.S., Horvath, L.G., Hussain, M., Jereczek-Fossa, Barbara A., Jones, R., Kanesvaran, R., Kellokumpu-Lehtinen, P.L., Khauli, R.B., Klotz, L., Kramer, G., Leibowitz, R., Logothetis, C.J., Mahal, B.A., Maluf, F. Cotait, Mateo, J., Matheson, D., Mehra, N., Merseburger, A., Morgans, A.K., Morris, M.J., Mrabti, H., Mukherji, D., Murphy, D.G.M., Murthy, V., Nguyen, P.L., Oh, W.K., Ost, P., O'Sullivan, J.M., Padhani, A.R., Pezaro, C., Poon, D.M.C., Pritchard, C.C., Rabah, D.M., Rathkopf, D., Reiter, R.E., Rubin, M.A., Ryan, C.J., Saad, F., Sade, J. Pablo, Sartor, O.A., Scher, H.I., Sharifi, N., Skoneczna, I., Soule, H., Spratt, D.E., Srinivas, S., Sternberg, C.N., Steuber, T., Oort, I.M. van, Zilli, T., Omlin, A., Gillessen, S., Bossi, A., Davis, I.D., Bono, J. de, Fizazi, K., James, N.D., Mottet, N., Shore, N., Small, E., Smith, M., Sweeney, C., Tombal, B., Antonarakis, E.S., Aparicio, A.M., Armstrong, A.J., Attard, G., Beer, T.M., Beltran, H., Bjartell, A., Blanchard, P., Briganti, A., Bristow, R.G., Bulbul, M., Caffo, O., Castellano, D., Castro, E., Cheng, H.H., Chi, K.N., Chowdhury, S., Clarke, C.S., Clarke, N., Daugaard, G., Santis, M. de, Duran, I., Eeles, R., Efstathiou, E., Efstathiou, J., Ekeke, O. Ngozi, Evans, C.P., Fanti, S., Feng, F.Y., Fonteyne, V., Fossati, N., Frydenberg, M., George, D., Gleave, M., Gravis, G., Halabi, S., Heinrich, D., Herrmann, K., Higano, C., Hofman, M.S., Horvath, L.G., Hussain, M., Jereczek-Fossa, Barbara A., Jones, R., Kanesvaran, R., Kellokumpu-Lehtinen, P.L., Khauli, R.B., Klotz, L., Kramer, G., Leibowitz, R., Logothetis, C.J., Mahal, B.A., Maluf, F. Cotait, Mateo, J., Matheson, D., Mehra, N., Merseburger, A., Morgans, A.K., Morris, M.J., Mrabti, H., Mukherji, D., Murphy, D.G.M., Murthy, V., Nguyen, P.L., Oh, W.K., Ost, P., O'Sullivan, J.M., Padhani, A.R., Pezaro, C., Poon, D.M.C., Pritchard, C.C., Rabah, D.M., Rathkopf, D., Reiter, R.E., Rubin, M.A., Ryan, C.J., Saad, F., Sade, J. Pablo, Sartor, O.A., Scher, H.I., Sharifi, N., Skoneczna, I., Soule, H., Spratt, D.E., Srinivas, S., Sternberg, C.N., Steuber, T., Oort, I.M. van, Zilli, T., and Omlin, A.

Abstract

Item does not contain fulltext, BACKGROUND: Innovations in imaging and molecular characterisation and the evolution of new therapies have improved outcomes in advanced prostate cancer. Nonetheless, we continue to lack high-level evidence on a variety of clinical topics that greatly impact daily practice. To supplement evidence-based guidelines, the 2022 Advanced Prostate Cancer Consensus Conference (APCCC 2022) surveyed experts about key dilemmas in clinical management. OBJECTIVE: To present consensus voting results for select questions from APCCC 2022. DESIGN, SETTING, AND PARTICIPANTS: Before the conference, a panel of 117 international prostate cancer experts used a modified Delphi process to develop 198 multiple-choice consensus questions on (1) intermediate- and high-risk and locally advanced prostate cancer, (2) biochemical recurrence after local treatment, (3) side effects from hormonal therapies, (4) metastatic hormone-sensitive prostate cancer, (5) nonmetastatic castration-resistant prostate cancer, (6) metastatic castration-resistant prostate cancer, and (7) oligometastatic and oligoprogressive prostate cancer. Before the conference, these questions were administered via a web-based survey to the 105 physician panel members ("panellists") who directly engage in prostate cancer treatment decision-making. Herein, we present results for the 82 questions on topics 1-3. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Consensus was defined as ≥75% agreement, with strong consensus defined as ≥90% agreement. RESULTS AND LIMITATIONS: The voting results reveal varying degrees of consensus, as is discussed in this article and shown in the detailed results in the Supplementary material. The findings reflect the opinions of an international panel of experts and did not incorporate a formal literature review and meta-analysis. CONCLUSIONS: These voting results by a panel of international experts in advanced prostate cancer can help physicians and patients navigate controversial areas of clinical manage

Published
2023

17. Testosterone Recovery and Associated Impact on Patient-Reported Health-Related Quality of Life (HRQoL) after Treatment with 6 Months of GnRH Agonist with or without Abiraterone Acetate plus Prednisone (AAP) and Apalutamide (Apa) in the FORMULA-509 Trial.

Author

Moningi, S., Nguyen, P.L., Rathkopf, D., Zurita-Saavedra, A., Spratt, D.E., Dess, R.T., Liauw, S., Szmulewitz, R., Einstein, D.J., Bubley, G., Yu, J.B., An, Y., Wong, A.C., Feng, F.Y., Mckay, R.R., Rose, B.S., Shin, K.Y., Taplin, M.E.A., Kollmeier, M.A., and Hoffman, K.E.

Subjects
*END of treatment, *OLDER men, *ABIRATERONE acetate, *GLEASON grading system, *TESTOSTERONE
Abstract

The FORMULA-509 trial randomized patients receiving salvage radiation between 6 months of GnRH agonist plus bicalutamide or 6 months of GnRH agonist plus AAP/Apa. Here we evaluate factors associated with testosterone recovery after trial treatment and the impact of testosterone recovery on patient-reported HRQoL. Testosterone was evaluated prior to treatment, at 3 months, at 6 months (end of systemic treatment), and at least every six months after treatment. Validated Expanded Prostate Cancer Index Composite (EPIC)-26 questionnaire was administered at baseline, end of treatment, and 1 year after completion of treatment. A change of 4 or more was considered a clinically meaningful change in the hormonal function domain. Log-rank test compared testosterone recovery between treatment groups. Wilcoxon rank sum and chi-square compared characteristics between those who did and did not recover testosterone. Multivariate logistic regression evaluated factors associated with lack of testosterone recovery. Chi-square evaluated frequency of clinically meaningful change in hormonal function. Three hundred forty-five patients were randomized (172 bicalutamide; 173 AAP/Apa). Median follow-up was 34 (6-53) months. There was no difference in testosterone recovery (>190 ng/dL) between treatment groups (p = 0.10). 52.6% [95% CI = 42.7-58.0] of patients recovered testosterone 6 months after treatment (bicalutamide: 51.2%; AAP/Apa 54.0%); 74.5% [69.8-79.2] 12 months (70.5%; 78.6%); 81.9% [77.7-86.1] 18 months (77.7%; 86.2%); and 88.8% [85.4-92.3] 30 months after treatment (85.8%; 91.9%). On univariate analysis, older age (median 67 vs 63 years; p<0.01), lower baseline testosterone (median 274 vs 379 ng/dL; p<0.01) and higher PSA at enrollment (median 0.3 vs 0.2; p = 0.02) were associated with lack of testosterone recovery 1 year after treatment. Race, Gleason score, and treatment arm were not associated with testosterone recovery. On multivariate analysis, age at enrollment, baseline testosterone, and PSA at enrollment remained significant (all p <0.05). In the subset of patients who completed EPIC-26 1 year after treatment (n = 219), those patients who did not have testosterone recovery were more likely to report a clinically meaningful decline in hormonal function relative to baseline than those who did achieve testosterone recovery, but it was not statistically significant (59% vs. 43% reporting clinically meaningful functional decline, p = 0.06). The addition of AAP/Apa did not lengthen time to testosterone recovery. Older men or those with lower baseline testosterone or higher PSA prior to treatment were less likely to recover testosterone 1 year after treatment. Patients who did not have testosterone recovery at 1 year were more likely to report decline in hormonal function. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

18. Characterizing the Performance of a Deep-Learning Segmentation Algorithm for Outlining Dominant Intraprostatic Lesions on Prostate Multi-Parametric MRI

Author

King, M.T., primary, Tsui, J.M.G., additional, Yang, D.D., additional, Peng, L.C., additional, Moningi, S., additional, Dee, E.C., additional, Guthier, C.V., additional, Pomerantz, M., additional, Orio, P.F., additional, DAmico, A.V., additional, Nguyen, P.L., additional, and Lee, L.K., additional

Published
2022
Full Text
View/download PDF

23. Long-Term Patient-Reported Health-Related Quality of Life in the Randomized FORMULA-509 Trial of Salvage Radiotherapy and 6 Months of GnRH Agonist with Either Bicalutamide or Abiraterone Acetate Plus Prednisone and Apalutamide after Radical Prostatectomy.

Author

Hoffman, K.E., Nguyen, P.L., Rathkopf, D., Zurita-Saavedra, A., Spratt, D.E., Dess, R.T., Liauw, S., Szmulewitz, R., Einstein, D.J., Bubley, G., Yu, J.B., An, Y., Wong, A.C., Feng, F.Y., Mckay, R.R., Rose, B.S., Lee, K.Y., Kibel, A., Taplin, M.E.A., and Kollmeier, M.A.

Subjects
*MATERIAL fatigue, *END of treatment, *FATIGUE (Physiology), *ABIRATERONE acetate, *NEUROBEHAVIORAL disorders
Abstract

The randomized FORMULA-509 trial demonstrated that for patients with a PSA > 0.5 after prostatectomy receiving salvage radiation and 6 months of GnRH Agonist, the addition of abiraterone acetate plus prednisone (AAP) and apalutamide (Apa) improved metastasis-free survival compared to bicalutamide. Here we present the patient-reported health-related quality of life (HRQoL) results through three years. Validated questionnaires were administered at baseline, end of treatment, and 1 and 3 years after completion of treatment. Patients completed Expanded Prostate Cancer Index Composite (EPIC)-26, PROMIS Fatigue, and Saint Louis University Mental Status Exam (SLUMS). EPIC-26 is scored from 0 to 100 with 100 indicating higher function. PROMIS Fatigue is scored using a standardized T score with higher score indicating greater fatigue. SLUMS is scored from 0 to 30 with 27 to 30 interpreted as normal, 21 to 26 as mild neurocognitive disorder and 20 or less as dementia. Scores between treatment arms were compared using the t-test. Results were interpreted using established thresholds for clinically meaningful differences (4-6 for EPIC-26 hormonal domain, 5-10 for PROMIS Fatigue). Three hundred forty-five patients were randomized (172 bicalutamide and 173 AAP/Apa). Completion rates at baseline, end of treatment, 1 year, and 3 years, were 96%, 80%, 70%, and 57% for EPIC-26; 95%, 79%, 67%, and 57% for PROMIS Fatigue; and 96%, 80%, 70%, and 34% for SLUMS. From baseline to end of treatment, both arms demonstrated clinically meaningful declines in EPIC-26 hormonal domain (median change -15 bicalutamide; -15 AAP/Apa) and increase in PROMIS Fatigue (median change 6 bicalutamide; 7.4 AAP/Apa). From end of treatment to 1 year after treatment patient-reported HRQoL improved to near baseline for both EPIC-26 hormonal function (bicalutamide median score baseline = 95, end = 75, 1 year = 90; AAP/Apa baseline = 95, end = 75, 1 year = 90) and fatigue (bicalutamide median score baseline = 43.1, end = 48.6, 1 year = 46.0; AAP/Apa baseline = 43.1, end = 51.0, 1 year = 46.0) with further improvement in EPIC-26 hormonal function at 3 years (bicalutamide = 95.0; AAP/Apa = 95.0) and stable fatigue at 3 years (bicalutamide = 46.0; AAP/Apa = 46.0). The cMedian SLUMS score was within normal range at baseline (27 bicalutamide; 27 AAP/Apa), end of treatment (28, 28) and 1 (27, 27) and 3 (27, 27) years after treatment. There was no difference in patient-reported hormonal function, fatigue, or mental status between treatment arms, at end of treatment (P = 0.40; P = 0.78; and P = 0.41, respectively), 1 year after treatment (P = 0.78; P = 0.89; and P = 0.76), and 3 years after treatment (P = 0.45; P = 0.95; and P = 0.86). The addition of AAP/Apa improved oncologic outcomes without causing a detectable difference in patient-reported hormonal function, fatigue, or mental status compared to bicalutamide through three years after treatment. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

25. Validation of a 22-gene Genomic Classifier in the NRG Oncology/RTOG 9202, 9413 and 9902 Phase III Randomized Trials: A Biopsy-Based Individual Patient Meta-Analysis in High-Risk Prostate Cancer

Author

Nguyen, P.L., primary, Huang, H.C., additional, Davicioni, E., additional, Sandler, H.M., additional, Shipley, W.U., additional, Efstathiou, J.A., additional, Simko, J., additional, Pollack, A., additional, Dicker, A.P., additional, Roach, M., additional, Rosenthal, S.A., additional, Morginstin, M., additional, Mendez, L., additional, Hartford, A.C., additional, Hall, W.A., additional, Desai, A.B., additional, Rabinovitch, R., additional, Peters, C.A., additional, Rodgers, J., additional, and Feng, F.Y., additional

Published
2021
Full Text
View/download PDF

28. Prognostic and Predictive Performance of Routine Clinicopathologic Variables in 10,535 Men Enrolled on Randomized Phase III Trials in Localized Prostate Cancer

Author

Dess, R.T., primary, Sun, Y., additional, Bolla, M., additional, Zapatero, A., additional, Malone, S., additional, Kishan, A.U., additional, Roy, S., additional, Jackson, W.C., additional, Lawton, C.A.F., additional, Sartor, O., additional, Nguyen, P.L., additional, Michalski, J.M., additional, Pisansky, T.M., additional, Roach, M., additional, Sandler, H.M., additional, Schipper, M., additional, Feng, F.Y., additional, and Spratt, D.E., additional

Published
2021
Full Text
View/download PDF

32. The Influence of the Pretreatment Host Immune State on Response to Radiation Therapy in High Risk Adenocarcinoma of the Prostate: A Validation Study from NRG Oncology/RTOG 0521 (Updated)

Author

Hall, W.A., primary, Karrison, T.G., additional, Rosenthal, S.A., additional, Amin, M., additional, Gomella, L.G., additional, Purdy, J.A., additional, Sartor, O., additional, Michalski, J.M., additional, Garzotto, M., additional, Bergom, C., additional, Jani, A., additional, Lawton, C.A.F., additional, Simko, J., additional, Moore, J., additional, Gore, E.M., additional, Lee, W.R., additional, Nguyen, P.L., additional, Danielson, B.L., additional, Sandler, H.M., additional, and Feng, F.Y., additional

Published
2020
Full Text
View/download PDF

34. Clinical-Genomic Sub-classification of High-Risk Prostate Cancer: Implications for Tailoring Therapy and Clinical Trial Design

Author

Muralidhar, V., primary, Alshalalfa, M., additional, Spratt, D.E., additional, Liu, S., additional, Karnes, R.J., additional, Schaeffer, E.M., additional, Davicioni, E., additional, Feng, F.Y., additional, Klein, E.A., additional, Tosoian, J., additional, Berlin, A., additional, Den, R.B., additional, and Nguyen, P.L., additional

Published
2020
Full Text
View/download PDF

47. The Impact of Persistently Elevated PSA after Prostatectomy in Men with Recurrent Prostate Cancer in NRG Oncology/RTOG 9601

Author

Birer, S., primary, Sun, Y., additional, Dess, R.T., additional, Jackson, W.C., additional, Efstathiou, J.A., additional, Zumsteg, Z.S., additional, Gharzai, L.A., additional, Kishan, A.U., additional, Mahal, B.A., additional, Nguyen, P.L., additional, Hall, W.A., additional, Morgan, T.M., additional, Michalski, J.M., additional, Zietman, A.L., additional, Schipper, M., additional, Feng, F.Y., additional, Sandler, H.M., additional, Spratt, D.E., additional, and Shipley, W.U., additional

Published
2020
Full Text
View/download PDF

48. NRG Oncology Updated International Consensus Atlas on Pelvic Lymph Node Volumes for Intact and Post-Operative Prostate Cancer

Author

Hall, W.A., primary, Paulson, E.S., additional, Davis, B.J., additional, Spratt, D.E., additional, Dearnaley, D., additional, Efstathiou, J.A., additional, Jani, A., additional, Buyyounouski, M.K., additional, Pisansky, T.M., additional, Tran, P.T., additional, Chen, R.C., additional, Cury, F., additional, Michalski, J.M., additional, Rosenthal, S.A., additional, Koontz, B.F., additional, Wong, A.C., additional, Tree, A., additional, Nguyen, P.L., additional, Feng, F.Y., additional, Sandler, H.M., additional, and Lawton, C.A.F., additional

Published
2020
Full Text
View/download PDF

50. Associations of Stromal Infiltration with Prognosis and Response to Postoperative Radiotherapy in Prostate Cancer

Author

Chen, W.S., primary, Mahal, B.A., additional, Alshalalfa, M., additional, Zhao, S.G., additional, Beltran, H., additional, Davicioni, E., additional, Karnes, R.J., additional, Ku, S.Y., additional, Lotan, T.L., additional, Rebbeck, T.R., additional, Schaeffer, E.M., additional, Feng, F.Y., additional, and Nguyen, P.L., additional

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results